ECSP077268A - Polimorfo ii de rapamicina y los usos de los mismos - Google Patents

Polimorfo ii de rapamicina y los usos de los mismos

Info

Publication number
ECSP077268A
ECSP077268A EC2007007268A ECSP077268A ECSP077268A EC SP077268 A ECSP077268 A EC SP077268A EC 2007007268 A EC2007007268 A EC 2007007268A EC SP077268 A ECSP077268 A EC SP077268A EC SP077268 A ECSP077268 A EC SP077268A
Authority
EC
Ecuador
Prior art keywords
rapamycin polymorph
same
polymorph
rapamycin
pharmaceutical compositions
Prior art date
Application number
EC2007007268A
Other languages
English (en)
Inventor
Mahdi Bakir Fawzi
Tianmin Zhu
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35431373&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP077268(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ECSP077268A publication Critical patent/ECSP077268A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención provee la Forma II del polimorfo de rapamicina. Esta invención además provee procesos para preparar la Forma II del polimorfo de rapamicina y las composiciones farmacéuticas que incluyen la Forma II del polimorfo de rapamicina
EC2007007268A 2004-08-20 2007-02-21 Polimorfo ii de rapamicina y los usos de los mismos ECSP077268A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60309604P 2004-08-20 2004-08-20

Publications (1)

Publication Number Publication Date
ECSP077268A true ECSP077268A (es) 2007-03-29

Family

ID=35431373

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2007007268A ECSP077268A (es) 2004-08-20 2007-02-21 Polimorfo ii de rapamicina y los usos de los mismos

Country Status (22)

Country Link
US (1) US7282505B2 (es)
EP (1) EP1781671A1 (es)
JP (1) JP2008510710A (es)
KR (1) KR20070051863A (es)
CN (1) CN101039948A (es)
AR (1) AR050374A1 (es)
AU (1) AU2005277407A1 (es)
BR (1) BRPI0514407A (es)
CA (1) CA2575887A1 (es)
CR (1) CR8929A (es)
EC (1) ECSP077268A (es)
GT (1) GT200500223A (es)
IL (1) IL181170A0 (es)
MX (1) MX2007002044A (es)
NO (1) NO20071050L (es)
PA (1) PA8642501A1 (es)
PE (1) PE20060649A1 (es)
RU (1) RU2007104518A (es)
SV (1) SV2006002201A (es)
TW (1) TW200608973A (es)
WO (1) WO2006023627A1 (es)
ZA (1) ZA200701453B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR040693A1 (es) 2002-07-30 2005-04-13 Wyeth Corp Formulaciones parenterales
KR20060085246A (ko) 2003-09-18 2006-07-26 마커사이트, 인코포레이티드 경공막 전달
US7349971B2 (en) * 2004-02-05 2008-03-25 Scenera Technologies, Llc System for transmitting data utilizing multiple communication applications simultaneously in response to user request without specifying recipient's communication information
US8551512B2 (en) * 2004-03-22 2013-10-08 Advanced Cardiovascular Systems, Inc. Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
DK1848431T3 (en) 2005-02-09 2016-04-18 Santen Pharmaceutical Co Ltd LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS
KR20140093764A (ko) 2006-02-09 2014-07-28 산텐 세이야꾸 가부시키가이샤 안정한 제제와 그 제조 및 사용 방법
ES2563288T3 (es) 2006-03-23 2016-03-14 Santen Pharmaceutical Co., Ltd Rapamicina en dosis bajas para el tratamiento de enfermedades relacionadas con la permeabilidad vascular
JP2010500286A (ja) * 2006-07-25 2010-01-07 アボット・ラボラトリーズ 結晶形態のラパマイシン類似体
US7820812B2 (en) 2006-07-25 2010-10-26 Abbott Laboratories Methods of manufacturing crystalline forms of rapamycin analogs
US7812032B2 (en) 2006-07-25 2010-10-12 Abbott Laboratories Crystalline forms of rapamycin analogs
US8486926B2 (en) * 2006-11-17 2013-07-16 Harbor Therapeutics, Inc. Steroid tetrol solid state forms
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8430055B2 (en) 2008-08-29 2013-04-30 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414910B2 (en) * 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
JP2008305262A (ja) * 2007-06-08 2008-12-18 Konica Minolta Business Technologies Inc サーバ及びシンクライアント環境でのプリンタ紹介方法
ES2645692T3 (es) 2008-11-11 2017-12-07 The Board Of Regents,The University Of Texas System Microcápsulas de rapamicina y su uso para el tratamiento del cáncer
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
CN102282457A (zh) * 2009-01-21 2011-12-14 拜康有限公司 确定西罗莫司稳定性的方法和制备其稳定形式的工艺
WO2010086863A2 (en) 2009-02-02 2010-08-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Crystalline drug-containing coatings
US20120252834A1 (en) * 2009-08-05 2012-10-04 The Government Of United States, As Represented By The Secretary Of The Army Novel use and method of rapamycin to treat toxic shock
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
US20140343128A1 (en) 2011-11-15 2014-11-20 Novartis Ag Combination of a phosphoinositide 3-kinase inhibitor and a modulator of the Janus Kinase 2 - Signal Transducer and Activator of Transcription 5 pathway
US20150224190A1 (en) 2012-07-06 2015-08-13 Mohamed Bentires-Alj Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the IL-8/CXCR interaction
WO2014160328A1 (en) 2013-03-13 2014-10-02 The Board Of Regents Of The University Of Texas System Mtor inhibitors for prevention of intestinal polyp growth
JP6529012B2 (ja) 2013-10-08 2019-06-12 エイアイ・セラピューティクス・インコーポレーテッド リンパ脈管筋腫症の処置のためのラパマイシン
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
EP3089737B1 (en) 2013-12-31 2021-11-03 Rapamycin Holdings, LLC Oral rapamycin nanoparticle preparations and use
MX2016010373A (es) * 2014-02-11 2016-11-30 Lam Therapeutics Inc Rapamicina para el tratamiento de linfangioleiomiomatosis.
US10307371B2 (en) 2014-02-11 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
HUP1400075A2 (hu) 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
NZ724756A (en) 2014-04-04 2023-07-28 Ai Therapeutics Inc An inhalable rapamycin formulation for treating age-related conditions
RU2732908C2 (ru) 2014-10-07 2020-09-24 ЭйАй ТЕРАПЬЮТИКС, ИНК. Ингаляционная лекарственная форма рапамицина для лечения легочной гипертензии
MA40910A (fr) 2014-11-07 2017-09-12 Civitas Therapeutics Inc Poudres de rapamycine pour administration pulmonaire
CN106478663A (zh) * 2015-08-26 2017-03-08 博瑞生物医药（苏州）股份有限公司 一种依维莫司的干燥方法
US20210154372A1 (en) 2017-05-15 2021-05-27 C.R. Bard, Inc. Medical device with drug-eluting coating and intermediate layer
CN109020995A (zh) * 2017-06-12 2018-12-18 鲁南制药集团股份有限公司 一种替西罗莫司的晶型物
EP3880266B1 (en) 2018-11-14 2025-05-07 Lutonix, Inc. Medical device with drug-eluting coating on modified device surface
EP3952937A1 (en) 2019-04-08 2022-02-16 Bard Peripheral Vascular, Inc. Medical device with drug-eluting coating on modified device surface

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
UA41884C2 (uk) * 1993-11-05 2001-10-15 Амерікан Хоум Продактс Корпорейшн Спосіб відокремлення рапаміцину від кислотних, основних та неполярних нейтральних домішок, присутніх в концентраті екстрактів ферментаційного бульйону або маточних розчинів

Also Published As

Publication number Publication date
PE20060649A1 (es) 2006-08-10
RU2007104518A (ru) 2008-09-27
SV2006002201A (es) 2006-05-09
ZA200701453B (en) 2010-08-25
GT200500223A (es) 2006-03-09
JP2008510710A (ja) 2008-04-10
EP1781671A1 (en) 2007-05-09
CA2575887A1 (en) 2006-03-02
PA8642501A1 (es) 2006-05-16
KR20070051863A (ko) 2007-05-18
CN101039948A (zh) 2007-09-19
MX2007002044A (es) 2007-03-29
WO2006023627A1 (en) 2006-03-02
CR8929A (es) 2007-08-28
IL181170A0 (en) 2007-07-04
NO20071050L (no) 2007-05-15
BRPI0514407A (pt) 2008-06-10
AR050374A1 (es) 2006-10-18
US7282505B2 (en) 2007-10-16
TW200608973A (en) 2006-03-16
US20060040971A1 (en) 2006-02-23
AU2005277407A1 (en) 2006-03-02
WO2006023627A8 (en) 2006-11-30

Similar Documents

Publication Publication Date Title
ECSP077268A (es) Polimorfo ii de rapamicina y los usos de los mismos
ECSP23004573A (es) Compuestos y composiciones como inhibidores de cinasa de proteina
DOP2006000193A (es) Compuestos de isoindol-imida y composiciones que los incluye y metodos para su uso
ECSP109937A (es) Pirimidil ciclopentanos como inhibidores de la proteína quinasa akt.
DOP2010000320A (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
SV2010003469A (es) Derivados de n- (arilamino) sulfonamidas que incluyen polimorfos como inhibidores de mek asi como las composiciones metodos de uso y de preparacion de los mismos
UY30369A1 (es) Compuestos de pirrolo-pirimidina y sus usos
ECSP088749A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
NI201000060A (es) COMPUESTOS DE TIENOPIRIMIDINA Y PIRAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE mTOR CINASA Y PI3 CINASA.
CL2011000691A1 (es) Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
PA8675701A1 (es) Nuevos derivados del fluoreno, composiciones que los contienen y su utilización
CR10600A (es) Ciclopenta (d) pirimidinas hidroxiladas y metoxiladas como inhibidores de akt proteina quinasa
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
CL2012002497A1 (es) Compuestos derivados de imidazopirimidina,sustituidos, inhibidores de la pde10a; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos psicoticos, esquizofrenia, enfermedad de parkinson, esclerosis multiple, entre otras.
CL2007003100A1 (es) Compuestos derivados de pirimidina, inhibidores de cisteina proteasa; procesos de preparacion; sales de los compuestos; composicion farmaceutica; y uso para el tratamiento de la malaria.
UY29601A1 (es) Arilpirazoles sustituidos
UY28671A1 (es) Pirido(2.3-d)pirimidina-2,4-diaminas como inhibidores de pde 2
ECSP088288A (es) DERIVADOS DE 7-(2-AMINO-1-HIDROXI-ETIL)-4-HIDROXIBENZOTIAZOL-2(3H)-ONA COMO AGONISTAS DE LOS ADRENOCEPTORES ß2
MX2016015874A (es) Derivados radiomarcadores de un compuesto de 2-amino-6-fluoro-n-[5 -fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida util como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparacion de tal compuesto y diferentes formas solidas del mismo.
CR9840A (es) Inhibidores de la pde y combinaciones de los mismos para el tratamiento de trastornos urologicos
ECSP11011344A (es) Nuevos anticuerpos anti-?5?1 y sus usos
UY31322A1 (es) Amidas heterocíclicas y sus métodos de uso-975
CO2020004977A2 (es) Compuestos bicíclicos para su uso como inhibidores de la ripi quinasa
UY29420A1 (es) Derivados de 2-piridona,composiciones que los contienen, procesos de preparación y aplicación
CR9257A (es) Polimorfo cci-779 y uso del mismo